COLLAGEN-POLYVINYLPYRROLIDONE FOR THE TREATMENT OF OSTEOARTHRITIS

The present invention refers to a down-modulator composition of chronic joint inflammation made of collagen-polyvinylpyrrolidone. Collagen turnover is modulated by collagen-PVP in patients with RA or OA due to the biocomplex down-regulates collagenolytic activity and up-regulates type III collagen content and tissue TIMP-1 similar to those levels observed in normal synovial tissue. Thus, chronic inflammatory process is altered by collagen-PVP action as previously described due to the down-regulation of IL-1², TNF-±, IL-8 and cell adhesion molecules because of all those molecules are capable of inducing activation and expression of collagenolytic enzymes as well as proliferation and migration of synovial cells through adhesive the mechanisms including cell adhesion molecules, and Cox-1 activation and induction. Besides, of cell anchorage, the interaction of extracellular matrix proteins-integrins generates signals that regulate MMPs expression, suggesting that cell adhesion molecules can also participate in tissue destruction associated to RA. On the other hand, down-regulation of TNF-± and IL-1² synthesis seems to stimulate apoptosis in synoviocytes. It seems to contribute to the inhibition of synovial cell proliferation and the pannus formation as well as joint tissue destruction.